4SC AG (LTS:0R6U) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R6U 4SC AG LTS:0R6U
8 GF Score
Price €6.47
GF Value €226.96
! 7 Warning Signs
View Full Analysis

What is 4SC AG Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0R6U
8GF Score
4SC AG LTS:0R6U
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 4SC AG (LTS:0R6U) Overvalued in 2026?

Based on GuruFocus' analysis, 4SC AG stock appears to be undervalued. The current stock price of €6.47 is trading 97.2% below its estimated GF Value™ of €226.96.

Key valuation signals for LTS:0R6U:

  • Short Ratio:
  • GF Value™: €226.96 vs. price of €6.47 (97.2% below fair value)
  • GF Score™: 8/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R6U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
8GF Score

Get the complete analysis for LTS:0R6U

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.47
Price
€226.96
GF Value